🔗 Share this article

While America undertakes historic adjustments to its vaccine recommendations, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by questioning coronavirus shots in the global health crisis and has focused upon alleged deaths following COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Program

Health officials planned to announce sweeping changes to the pediatric immunization program earlier this month, synchronizing the US with the Danish national calendar, it is understood – a significant shift that would place the US out of step with many the global community with no evidence for improved outcomes. The planned update has been pushed back until the next year.

Rather than the director of the vaccine center, Høeg is listed to present at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to lead the office this year.

Consolidating Power at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics branches as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

The new acting director has often pushed for ending some childhood vaccine recommendations in the US to become more like the Danish model, a country with universal health coverage and a number of inhabitants about the size of Wisconsin’s.

So far comments, she has kept her attention on vaccination policy – usually the responsibility of Prasad, chief of the FDA’s CBER – instead of drug regulation.

Concerns Over Background

Høeg has little discernible background in pharmaceutical research, oversight or administrative roles, which has been customary for past leaders of the CBER. She has been employed at the FDA as a key advisor to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in managing a major agency. She is not an expert in drug approvals.”

Previous directors of the center would “be deeply familiar with regulatory frameworks and the research of drug development”, said Dr. Janet Woodcock. “Objectively, she lacks the type of experience that previous people who ran CBER have had.”

The drug center has an vast workload at the FDA, the former commissioner emphasized.

“Everybody just pays attention on the new drug program, but the generic drug division authorizes numerous off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and so forth, and every single one must be looked after,” Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a significant administrative component to the job, which manages in excess of 5,000 staff members. “It’s a massive leadership role, if you perform it correctly,” she said.

Agency Reaction and Controversial Policies

When asked about inquiries about Dr. Høeg's fitness for the role and whether this assignment indicates increased cooperation among regulatory chiefs on vaccines, a press secretary responded that the “questions rely on flawed assumptions”.

“Her experience aligns with the responsibilities of her role,” the spokesperson stated, pointing to the months Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new priority voucher program, a disputed expedited medication authorization process that reportedly troubled her former heads. “How are these medications being picked for this expedited pathway? Who is making the choices?” Howard said. “There is a lot of confidentiality happening at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards less stringent oversight of pharmaceuticals, with the exception of vaccines.”

Documented History on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if troubling, history, Howard said. She authored a analysis using unverified volunteer-provided data to assess the frequency of myocarditis after Covid immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are riskier than they are.

Among her “desired changes” for the incoming government encompassed revising regulations for recently developed shots and discontinuing “non-essential” immunizations, she stated following the vote on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of excluding adolescent males from receiving Covid vaccines.

“She’s an all-around ideologue who commences with her preconceived notions and works backwards to accommodate the evidence in a highly misleading, untruthful manner,” Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg joined other dissenters, {like|